The results showed that higher TNFR2 expression was associated with higher TIDE scores, complying with poorer responses to ICIs therapy, in patients with BRCA, HCC, LUSC, and MELA (Figures 2E–H). The gene discussed is TNFRSF1B; the disease is hepatocellular carcinoma.